Filgrastim

Generic Name: Filgrastim

Brand Names: Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim

Drug Type: Biotech

Chemical Formula: -

CAS Number: 121181-53-1

Unique Ingredient Identifier: PVI5M0M1GW

Background: Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...

Indication: Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...

Associated Conditions: Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia

Associated Therapies: Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy

Clinical Trials

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Palifermin
Drug: Panobinostat
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Drug: Rituximab
Drug: Dexamethasone
Drug: Caphosol
Drug: Glutamine
Other: Oral Cryotherapy (ice chips)
Drug: Pyridoxine
Biological: Stem Cell Infusion
Drug: G-CSF

First Posted Date: 2016-11-11

Last Posted Date: 2017-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02961816

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Phase 1

Terminated

Conditions: Cancer
Neuroendocrine Tumors
Tumors
Neoplasms

Interventions: Drug: TAS-102
Drug: Temozolomide
Drug: Filgrastim
Drug: Pegfilgrastim

First Posted Date: 2016-10-25

Last Posted Date: 2022-09-23

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 18

Registration Number: NCT02943733

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Phase 2

Completed

Conditions: Fanconi Anemia

Interventions: Drug: filgrastim
Drug: plerixafor

First Posted Date: 2016-10-12

Last Posted Date: 2020-05-27

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 13

Registration Number: NCT02931071

Locations: 🇪🇸
Hospital Infantil Universitario Niño Jesus, Madrid, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Phase 2

Completed

Conditions: Severe Aplastic Anemia

Interventions: Drug: Antithymocyte Globulin (ATG)
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation (TBI)
Procedure: Haplo HSCT
Drug: Tacrolimus
Drug: Mycophenolate mofetil (MMF)
Drug: G-CSF

First Posted Date: 2016-09-28

Last Posted Date: 2022-11-30

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 32

Registration Number: NCT02918292

Locations: 🇺🇸
Johns Hopkins Unversity, Baltimore, Maryland, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States

and more 25 locations

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Not Applicable

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: melphalan
Drug: fludarabine
Drug: thiotepa
Drug: Cyclophosphamide
Drug: Mesna
Drug: Mycophenolate Mofetil
Drug: Filgrastim
Drug: Tacrolimus

First Posted Date: 2016-08-26

Last Posted Date: 2024-12-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 44

Registration Number: NCT02880293

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis

Not Applicable

Conditions: Intrauterine Adhesion

Interventions: Drug: Normal saline
Drug: G-CSF
Drug: hormone therapy
Other: Cook balloon

First Posted Date: 2016-08-04

Last Posted Date: 2018-01-05

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 240

Registration Number: NCT02855632

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Phase 1

Withdrawn

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Omacetaxine
Drug: Azacitidine
Drug: G-CSF

First Posted Date: 2016-07-18

Last Posted Date: 2017-05-03

Lead Sponsor: University of Florida

Registration Number: NCT02835794

Locations: 🇺🇸
University of Florida Health Shands Cancer Hospital, Gainesville, Florida, United States

Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment

Conditions: Blood Diseases

First Posted Date: 2016-06-21

Last Posted Date: 2016-06-21

Lead Sponsor: Azienda Ospedaliera San Giovanni Battista

Target Recruit Count: 300

Registration Number: NCT02806791

Locations: 🇮🇹
Aou Citta' Della Salute E Della Scienza Di Torino, Divisione Di Ematologia, Sscvd Trapianto Allogenico, Torino, Italy

Proteomics and Stem Cell Therapy as a New Vascularization Strategy

Not Applicable

Completed

Conditions: Critical Limb Ischemia

Interventions: Device: Pneumatic calf compression
Drug: Filgrastim

First Posted Date: 2016-06-16

Last Posted Date: 2021-11-15

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 9

Registration Number: NCT02802852

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)
Chronic Lymphocytic Leukemia (CLL)
Chemotherapy-sensitive Lymphoma
Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
Acute Myelogenous Leukemia (AML)
Acute Biphenotypic Leukemia (ABL)
Acute Undifferentiated Leukemia (AUL)

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
Radiation: Total Body Irradiation (TBI) 200cGy on Day -1
Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
Drug: Busulfan
Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
Procedure: Infusion of non-T-cell depleted bone marrow on Day 0
Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: G-CSF
Drug: Pre-HCT Mesna on Days -2 and -1
Drug: Pre-HCT Mesna on Days -5 and -4
Drug: Pre-HCT Mesna on Days -6 and -5
Drug: Post-HCT Mesna

First Posted Date: 2016-06-08

Last Posted Date: 2020-12-02

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 80

Registration Number: NCT02793544

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center - Adults, New York, New York, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program, Richmond, Virginia, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy